罗欣药业：终止协议转让公司部分股份

Core Viewpoint - The share transfer agreement between major shareholders of Luoxin Pharmaceutical (002793) and Kangqi Fund has been terminated, which was originally intended to transfer 5% of the company's total share capital [1] Group 1 - The termination of the share transfer agreement does not lead to any changes in the company's controlling shareholder or actual controller [1] - The termination will not have a significant impact on the company's governance structure or ongoing operations [1] - There are no circumstances that would harm the interests of the company or minority investors [1]